Table 1.
Baseline characteristics stratified by disease cohort and treatmenta
| Characteristic | All patients (N = 2401) | PsO only (n = 1970) | PsO with comorbid PsA (n = 431) | Secukinumab (n = 1383) | Etanercept (n = 326) | Placebo (n = 692) |
|---|---|---|---|---|---|---|
| Age, mean (SD), years | 44.5 (13.2) | 44.0 (13.3) | 47.2 (12.3) | 44.8 (13.4) | 42.8 (13.0) | 44.8 (13.0) |
| Missing, n (%) | 435 (18.1) | 359 (18.2) | 76 (17.6) | 249 (18.0) | 73 (22.39) | 113 (16.33) |
| Male, n (%) | 1678 (69.9) | 1427 (72.4) | 251 (58.2) | 962 (69.6) | 232 (71.2) | 484 (69.9) |
| Race, n (%) | ||||||
| Asian | 453 (18.9) | 404 (20.5) | 49 (11.4) | 25 (18.7) | 74 (22.7) | 121 (17.5) |
| Black | 35 (1.5) | 32 (1.6) | 3 (0.7) | 22 (1.6) | 0 | 13 (1.9) |
| White | 1732 (72.1) | 1370 (69.5) | 362 (84.0) | 1004 (72.6) | 219 (67.2) | 509 (73.6) |
| Native American | 117 (4.9) | 109 (5.5) | 8 (1.9) | 62 (4.5) | 27 (8.3) | 28 (4.0) |
| Other | 51 (2.1) | 45 (2.3) | 6 (1.4) | 29 (2.1) | 4 (1.2) | 18 (2.6) |
| Pacific Islander | 7 (0.3) | 4 (0.2) | 3 (0.7) | 5 (0.4) | 1 (0.3) | 1 (0.1) |
| Unknown | 6 (0.3) | 6 (0.3) | 0 | 3 (0.2) | 1 (0.3) | 2 (0.3) |
| Time since first diagnosis of psoriasis, mean (SD), years | 17.4 (12.2) | 16.4 (11.8) | 21.5 (13.3) | 17.5 (12.3) | 16.5 (12.0) | 17.0 (12.2) |
| Diagnosis of PsA | ||||||
| Yes, n (%) | 431 (18.0) | – | 431 (100.0) | 250 (18.1) | 44 (13.5) | 137 (19.8) |
| Time since first diagnosis of PsA, mean (SD), years | 8.6 (8.8) | – | 8.6 (8.8) | 7.7 (7.9) | 9.5 (11.6) | 9.9 (9.0) |
| Prior therapy, n (%) | ||||||
| Systemic | 1520 (63.3) | 1204 (61.1) | 316 (73.3) | 886 (64.1) | 214 (65.6) | 420 (60.7) |
| Biologic | 501 (20.8) | 358 (18.2) | 143 (33.2) | 308 (22.3) | 45 (13.8) | 148 (21.4) |
| Baseline PASI scores, mean (SD) | 22.7 (9.7) | 22.8 (9.8) | 22.3 (9.3) | 22.7 (9.7) | 23.2 (9.8) | 22.5 (9.7) |
| Baseline DLQI domain scores (0–6), mean (SD) | ||||||
| Daily activities | 2.77 (1.79) | 2.71 (1.77) | 3.08 (1.86) | 2.80 (1.79) | 2.79 (1.80) | 2.83 (1.78) |
| Leisure activities | 2.42 (1.92) | 2.37 (1.88) | 2.66 (2.06) | 2.45 (1.92) | 2.58 (1.94) | 2.30 (1.91) |
| Symptoms and feelings | 3.79 (1.51) | 3.73 (1.50) | 4.05 (1.54) | 3.85 (1.50) | 3.67 (1.58) | 3.72 (1.52) |
DLQI Dermatology Life Quality Index, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, PsO psoriasis
aBased on available data